Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer

키워드

참고문헌 (78)

1. La Vecchia C, "Thyroid cancer mortality and incidence: a global overview", Int J Cancer, 136, pp.2187~2195 (2015)
2. Nikiforov YE., "Thyroid carcinoma: molecular pathways and therapeutic targets", Mod Pathol, 21(Suppl 2), pp.S37~S43 (2008)
3. Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
4. Wallace DC., "Mitochondria and cancer", Nat Rev Cancer, 12, pp.685~698 (2012)
5. Ashrafi G, "The pathways of mitophagy for quality control and clearance of mitochondria", Cell Death Differ, 20, pp.31~42 (2013)
6. Park J, "Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin", Nature, 441, pp.1157~1161 (2006)
7. Fusco A, "A new mechanism of BRAF activation in human thyroid papillary carcinomas", J Clin Invest, 115, pp.20~23 (2005)
8. Santoro M, "RET", PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture, 2006, pp.155, 645~653
9. Kimura ET, "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
10. Liu D, "BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells", J Clin Endocrinol Metab, 92, pp.2264~2271 (2007)
11. Lee SJ, "Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma", PLoS One, 6, pp.e16180~ (2011)
12. Xing M., "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
13. Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309, pp.1493~1501 (2013)
14. Xing M., "BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
15. Liu Z, "Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase", akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers, 2008, pp.93, 3106~3116
16. Vasko V, "Specific pattern of RAS oncogene mutations in follicular thyroid tumors", J Clin Endocrinol Metab, 88, pp.2745~2752 (2003)
17. Gire V, "RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation", Oncogene, 19, pp.737~744 (2000)
18. Kim DW, "RET", PTC (rearranged in transformation, Mol Endocrinol, pp.2003, 17[DOI]
19. Jung HS, "Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET", PTC kinases, 2005, pp.19, 2748~2759
20. Hwang JH, "Activation of signal transducer and activator of transcription 3 by oncogenic RET", PTC (rearranged in transformation, Mol Endocrinol, pp.2003, 17[DOI]
21. Kim DW, "Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)", papillary thyroid carcinoma (PTC), 2007, pp.21, 3039~3049
22. Kim YR, "Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET", PTC, 2008, pp.8, 144~
23. Kim H, "Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling", J Immunol, 171, pp.171~616 (2003)
24. Suh JM, "Regulation of the phosphatidylinositol 3-kinase, Akt", protein kinase B, FRAP, J Biol Chem, pp.2003, 278[DOI]
25. Kim DW, "An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET", papillary thyroid cancer kinases, 2006, pp.91, 4070~4076
26. Hwang ES, "Regulation of signal transducer and activator of transcription 1 (STAT1)and STAT1-dependent genes by RET", PTC (rearranged in transformation, Mol Endocrinol, pp.2004, 18[DOI]
27. Fagin JA, "High prevalence of mutations of the p53gene in poorly differentiated human thyroid carcinomas", J Clin Invest, 91, pp.179~184 (1993)
28. Garcia-Rostan G, "Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma", Cancer Res, 59, pp.1811~1815 (1999)
29. Gustafson S, "Cowden syndrome", Semin Oncol, 34, pp.428~434 (2007)
30. Hemerly JP, "Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas", Eur J Endocrinol, 163, pp.747~755 (2010)
31. Murugan AK, "Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers", Endocr Pathol, 22, pp.97~102 (2011)
32. Murugan AK, "Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene", Cancer Res, 71, pp.4403~4411 (2011)
33. Eberhardt NL, "The role of the PAX8", PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer, 2010, pp.321, 50~56
34. Ciampi R, "Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer", J Clin Invest, 115, pp.94~101 (2005)
35. Jo YS, "Significance of the expression of major histocompatibility complex class II antigen, HLADR and -DQ, with recurrence of papillary thyroid cancer", Int J Cancer, 122, pp.785~790 (2008)
36. Chung HK, "Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis", J Clin Endocrinol Metab, 88, pp.3913~3920 (2003)
37. Hwang JH, "CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells", J Clin Endocrinol Metab, 88, pp.408~416 (2003)
38. Ward PS, "Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate", Cancer Cell, 21, pp.297~308 (2012)
39. Kim SJ, "CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane", Cell Metab, 16, pp.274~283 (2012)
40. Brookes PS, "Calcium, ATP, and ROS: a mitochondrial love-hate triangle", Am J Physiol Cell Physiol, 287, pp.C817~C833 (2004)
41. Stratton MR, "The cancer genome", Nature, 458, pp.719~724 (2009)
42. Bartoletti-Stella A, "Mitochondrial DNA mutations in oncocytic adnexal lacrimal glands of the conjunctiva", Arch Ophthalmol, 129, pp.664~666 (2011)
43. Brandon M, "Mitochondrial mutations in cancer", Oncogene, 25, pp.4647~4662 (2006)
44. Chinnery PF, "Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism?", Lancet, 360, pp.1323~1325 (2002)
45. Copeland WC, "Mitochondrial DNA alterations in cancer", Cancer Invest, 20, pp.557~569 (2002)
46. Gasparre G, "Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma", Hum Mol Genet, 17, pp.986~995 (2008)
47. Pereira L, "Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors", BMC Cancer, 12, pp.53~ (2012)
48. Yeh JJ, "Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours", Oncogene, 19, pp.2060~2066 (2000)
49. Gasparre G, "Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors", Proc Natl Acad Sci U S A, 104, pp.9001~9006 (2007)
50. Bonora E, "Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III", Cancer Res, 66, pp.6087~6096 (2006)
51. Maximo V, "Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors", Am J Pathol, 160, pp.1857~1865 (2002)
52. Rogounovitch TI, "Large deletions in mitochondrial DNA in radiation-associated human thyroid tumors", Cancer Res, 62, pp.7031~7041 (2002)
53. Berho M, "The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15cases", Hum Pathol, 28, pp.47~53 (1997)
54. Hong JH, "Implications of oncocytic change in papillary thyroid cancer", Clin Endocrinol (Oxf ), 85, pp.797~804 (2016)
55. Lee MH, "Thyroid dysfunction associated with follicular cell steatosis in obese male mice and humans", Endocrinology, 156, pp.1181~1193 (2015)
56. Le Pennec S, "Nitric oxide and calcium participate in the fine regulation of mitochondrial biogenesis in follicular thyroid carcinoma cells", J Biol Chem, 286, pp.18229~18239 (2011)
57. Raharijaona M, "PGC-1-related coactivator modulates mitochondrial-nuclear crosstalk through endogenous nitric oxide in a cellular model of oncocytic thyroid tumours", PLoS One, 4, pp.e7964~ (2009)
58. Ferreira-da-Silva A, "Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration", PLoS One, 10, pp.e0122308~ (2015)
59. Chiappetta G, "The RET", PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions, 2002, pp.87, 364~369
60. Bromberg JF, "Stat3as an oncogene", Cell, 98, pp.295~303 (1999)
61. Gough DJ, "Mitochondrial STAT3 supports Ras-dependent oncogenic transformation", Science, 324, pp.1713~1716 (2009)
62. de la Iglesia N, "Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway", Genes Dev, 22, pp.449~462 (2008)
63. Musteanu M, "Stat3 is a negative regulator of intestinal tumor progression in Apc(Min)mice", Gastroenterology, 138, pp.1003~1011 (2010)
64. Schneller D, "p19(ARF)", p14(ARF)controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma, 2011, pp.54, 164~172
65. Couto JP, "STAT3 negatively regulates thyroid tumorigenesis", Proc Natl Acad Sci U S A, 109, pp.E2361~E2370 (2012)
66. Lee MH, "Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E", J Clin Endocrinol Metab, 96, pp.E19~E30 (2011)
67. Howell GM, "RAS mutations in thyroid cancer", Oncologist, 18, pp.926~932 (2013)
68. Davis RJ., "The mitogen-activated protein kinase signal transduction pathway", J Biol Chem, 268, pp.14553~14556 (1993)
69. Xing M., "Genetic alterations in the phosphatidylinositol-3 kinase", Akt pathway in thyroid cancer, 2010, pp.20, 697~706
70. Abubaker J, "Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population", J Clin Endocrinol Metab, 93, pp.611~618 (2008)
71. Hou P, "Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase", AKT signaling pathway in thyroid tumors, 2008, pp.113, 2440~2447
72. Chiaradonna F, "Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts", Biochim Biophys Acta, 1757, pp.1338~1356 (2006)
73. Weinberg F, "Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity", Proc Natl Acad Sci U S A, 107, pp.8788~8793 (2010)
74. Hu Y, "K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis", Cell Res, 22, pp.399~412 (2012)
75. Marchenko ND, "Death signal-induced localization of p53 protein to mitochondria: a potential role in apoptotic signaling", J Biol Chem, 275, pp.16202~16212 (2000)
76. Compton S, "Mitochondrial dysfunction impairs tumor suppressor p53 expression", function, 2011, pp.286, 20297~20312
77. Ni Y, "Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowdenlike syndrome via FAD", NAD-dependant destabilization of p53, 2012, pp.21, 300~310
78. Lee J, "Dysregulation of Parkin-mediated mitophagy in thyroid Hurthle cell tumors", Carcinogenesis, 36, pp.1407~1418 (2015)

관련 논문AI추천